Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions.
|Articles|January 27, 2023
AJMC® in the Press, January 27, 2023
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
A study published in the November 2022 issue of The American Journal of Managed Care® was cited in articles by
Advertisement
Related to this article
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.
A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.
Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
3
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5